Articles published by BeOne Medicines Ltd.

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
From BeOne Medicines Ltd.
Via Business Wire
Tickers ONC
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.